Erratum: A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis (Gut (2020) 69 (1148–1149) DOI: 10.1136/gutjnl-2020-321183);A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis

Gut

Volumn 69, Issue 6, 2020, Pages 1148-1149

  Mazza, Stefano ^a   Sorce, Andrea ^a   Peyvandi, Flora ^a,b   Vecchi, Maurizio ^a,b   Caprioli, Flavio ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

inflammatory bowel disease; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HYDROXYCHLOROQUINE; LOPINAVIR PLUS RITONAVIR; MESALAZINE; METHYLPREDNISOLONE; PREDNISONE; ANTIVIRUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ANEMIA; BLOODY DIARRHEA; CASE REPORT; CLINICAL ARTICLE; CLOSTRIDIOIDES DIFFICILE; COLON ULCER; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; DEATH; DISEASE DURATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FECES CULTURE; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LETTER; NONINVASIVE VENTILATION; PRIORITY JOURNAL; RELAPSE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SIGMOIDOSCOPY; THORAX RADIOGRAPHY; THROAT CULTURE; ULCERATIVE COLITIS; VERY ELDERLY; VIRUS PNEUMONIA; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; FATALITY; LABORATORY TECHNIQUE; PANDEMIC;

AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; BETACORONAVIRUS; CLINICAL LABORATORY TECHNIQUES; COLITIS, ULCERATIVE; CORONAVIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HUMANS; MESALAMINE; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083228933     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2020-321183corr1     Document Type: Erratum

References (10)

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-9.
3. Guan W-jie, Ni Z-yi, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med Overseas Ed 2020.
4. IOIBD Update on COVID19 for Patients with Crohn's Disease and Ulcerative Colitis. Available: Https://www. ioibd. org/ioibd-update-on-covid19-for-patients-withcrohns-disease-and-ulcerative-colitis/[Accessed 15 Mar 2020].
5. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance, 13 March 2020 (license: CC BY-NC-SA 3.0 IGO). World Health Organization, 2020. https://apps. who. int/iris/handle/10665/331446
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62.
7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.0994
8. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 2004;59:252-6.
9. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020. doi:10.1056/NEJMoa2001282
10. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.